SLS Company Profile and Key Details
SELLAS Life Sciences Group
Price Chart
Stock Price Today
SELLAS Life Sciences Group, Inc. (SLS) stock surged +2.72%, trading at $4.15 on NASDAQ, up from the previous close of $4.04. The stock opened at $3.99, fluctuating between $3.97 and $4.27 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 20, 2026 | 4.00 | 4.27 | 3.97 | 4.15 | 5.73M |
| Feb 19, 2026 | 3.85 | 4.23 | 3.79 | 4.04 | 7.48M |
| Feb 18, 2026 | 3.65 | 3.82 | 3.57 | 3.79 | 3.22M |
| Feb 17, 2026 | 3.59 | 3.75 | 3.52 | 3.66 | 4.04M |
| Feb 13, 2026 | 3.56 | 3.66 | 3.51 | 3.59 | 2.42M |
| Feb 12, 2026 | 3.63 | 3.69 | 3.46 | 3.55 | 3.31M |
| Feb 11, 2026 | 3.61 | 3.74 | 3.52 | 3.67 | 4.17M |
| Feb 10, 2026 | 3.81 | 3.90 | 3.68 | 3.76 | 3.45M |
| Feb 09, 2026 | 3.77 | 3.84 | 3.62 | 3.81 | 4.02M |
| Feb 06, 2026 | 3.59 | 3.83 | 3.55 | 3.73 | 5.43M |
| Feb 05, 2026 | 3.81 | 3.89 | 3.49 | 3.53 | 6.71M |
| Feb 04, 2026 | 4.16 | 4.18 | 3.76 | 3.82 | 6.1M |
| Feb 03, 2026 | 3.98 | 4.20 | 3.94 | 4.16 | 4.54M |
| Feb 02, 2026 | 3.70 | 4.12 | 3.66 | 3.97 | 5.55M |
| Jan 30, 2026 | 3.85 | 3.89 | 3.67 | 3.77 | 5.38M |
| Jan 29, 2026 | 3.97 | 4.06 | 3.76 | 3.89 | 5.83M |
| Jan 28, 2026 | 4.44 | 4.67 | 3.96 | 3.97 | 6.4M |
| Jan 27, 2026 | 4.25 | 4.61 | 4.05 | 4.40 | 5.71M |
| Jan 26, 2026 | 4.25 | 4.38 | 4.08 | 4.30 | 5.13M |
| Jan 23, 2026 | 4.52 | 4.53 | 4.24 | 4.26 | 3.93M |
Contact Details
About Company
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Company Information
| Employees | 15 |
| Beta | 2.25 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Frequently Asked Questions
Vice President and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality
Mr. Jörg W. Breitkopf
Head of Clinical Operations
Mr. Robert M. Francomano
Senior Vice President & Chief Commercial Officer
Dr. Angelos M. Stergiou M.D., ScD h.c.
Founder, Pres, Chief Executive Officer & Director
Ms. Barbara A. Wood
Executive Vice President, Gen. Counsel & Sec.
Dr. Dragan Cicic M.D., MBA
Senior Vice President of Clinical Devel.
Mr. John Thomas Burns CPA
Senior Vice President & Chief Financial Officer
Ms. Barbara A. Wood Esq.
Executive Vice President, Gen. Counsel & Corporation Sec.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep